Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Go back to Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Ovid Therapeutics (OVID) Climbs 80% Following Pact with Takeda on Soticlestat

March 3, 2021 7:14 AM EST

Ovid Therapeutics (NASDAQ: OVID) Climbs 80% Following Pact with Takeda on Soticlestat

Earlier Takeda (TAK) Secures Global Rights from Ovid Therapeutics (OVID) to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome... More